Skip to main content
Shenyang Xingqi Pharmaceutical Co., Ltd. logo

Shenyang Xingqi Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300573 ISIN · CNE100002DV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,236 across all filing types
Latest filing 2025-10-30 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300573

About Shenyang Xingqi Pharmaceutical Co., Ltd.

https://www.sinqi.com

Shenyang Xingqi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of ophthalmic medications. The company provides a comprehensive portfolio of eye care solutions targeting conditions such as myopia, dry eye syndrome, glaucoma, and ocular infections. Key products include low-dose atropine sulfate eye drops for slowing myopia progression in children, cyclosporine eye drops for dry eye, and various anti-infective and anti-inflammatory agents. The firm operates advanced manufacturing facilities and maintains a robust R&D pipeline focused on innovative drug delivery systems and therapeutic treatments for vision health. By integrating clinical research with industrial production, the company serves as a major provider of specialized ophthalmic pharmaceuticals, addressing diverse clinical needs in the field of ophthalmology.

Recent filings

Filing Released Lang Actions
关于沈阳兴齐眼药股份有限公司申请向特定对象发行股票的审核问询函的回复（豁免版）
Capital/Financing Update Classification · 95% confidence The document is a detailed response to an inquiry letter from the Shenzhen Stock Exchange regarding a company's application for a specific share issuance to targeted investors. It contains extensive financial data, product market analysis, competitive landscape, R&D projects, and regulatory compliance information. The content is focused on explaining and justifying financial and operational aspects related to a capital raising event, specifically a private placement of shares. The document is not a general annual or quarterly report, nor is it an earnings release or audit report. It is not a simple announcement but a comprehensive reply to regulatory questions about a capital issuance. Therefore, the document fits best under the category of Capital/Financing Update (CAP), as it relates to the company's fundraising activities and the regulatory review process for a specific share issuance.
2025-10-30 Chinese
国泰海通证券股份有限公司关于沈阳兴齐眼药股份有限公司向特定对象发行股票之发行保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" (Issuance Sponsorship Letter) related to a specific stock issuance by 沈阳兴齐眼药股份有限公司. It details the underwriting and sponsorship of a targeted share issuance (向特定对象发行股票) to be listed on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). The content includes detailed information about the underwriting institution, the issuance plan, pricing, shareholding structure, financial data, and regulatory compliance. This document is a formal sponsorship letter issued by the underwriting institution to support the company's targeted share issuance and listing. It is not an annual report, earnings release, or a general regulatory filing but a detailed capital/financing update related to a specific stock issuance and listing process. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed financial and issuance information support this classification with high confidence.
2025-10-30 Chinese
发行人最近一年的财务报告及其审计报告以及最近一期的财务报告
Regulatory Filings
2025-10-30 Chinese
2025年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '沈阳兴齐眼药股份有限公司2025 年第三季度报告' which translates to 'Shenyang Xingqi Eye Medicine Co., Ltd. 2025 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial indicators for the third quarter of 2025. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the period. It is not an announcement or a brief summary but a full financial report for a period shorter than a full fiscal year. There is no indication that this is an annual report, audit report, or any other type of filing. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). The document length is over 13,000 characters, indicating it is a full report, not just an announcement or certification. 9M 2025
2025-10-28 Chinese
关于完成工商变更登记的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the completion of a business registration change, specifically about the change in registered capital and amendment of the company bylaws. It references previous announcements about the capital change and shareholder meeting resolutions. The document is short (785 characters) and serves as a formal notice of the completion of registration with the market supervision authority. It does not contain financial statements, detailed financial data, or management discussion. It is not a report but an announcement of a corporate action related to capital change and registration. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA).
2025-10-14 Chinese
关于SQ-129玻璃体缓释注射液获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding the approval of a clinical trial for a new drug by the National Medical Products Administration (国家药品监督管理局). It details the drug name, indications, approval number, and regulatory compliance. The document is short (1106 characters) and serves as an official notification of regulatory approval rather than a financial report or detailed corporate filing. It does not contain financial data, management changes, voting results, or other typical corporate filing content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-10-09 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.